While not reflected in official classifications yet, there is evidence that the negative prognostic impact of HGBL with BCL2 and MYC translocations (HGBL‐MYC/BCL2) is confined to cases where MYC is juxtaposed to an immunoglobulin (IG) partner.27, 29. The gene discussed is MYC; the disease is high grade B-cell lymphoma.